Clinuvel Pharmaceuticals Limited (AU:CUV) has released an update.
Clinuvel Pharmaceuticals Limited has announced the cessation of 17,100 ordinary shares due to an on-market buy-back and the lapse of 10,750 performance rights as conditional requirements were not met, both actions effective as of September 30, 2024. This move is part of the company’s capital management strategy and could signal a shift in Clinuvel’s market position.
For further insights into AU:CUV stock, check out TipRanks’ Stock Analysis page.
